3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Glioblastoma
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Gliosarcoma
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
Doxorubicin
80
Ifosfamide
54
Radiotherapy
43
Filgrastim
41
Gemcitabine
38
Cyclophosphamide
34
Etoposide
26
Vincristine
24
Cisplatin
24
Docetaxel
23
pazopanib
21
Trabectedin
19
Carboplatin
17
pembrolizumab
15
Peripheral Blood Stem Cell Transplantation
14
eribulin
12
Mesna
12
Melphalan
12
Sorafenib
11
Sirolimus
11
Irinotecan
11
Granulocyte Colony-Stimulating Factor
11
Bevacizumab
11
Topotecan
10
Paclitaxel
10
Imatinib Mesylate
10
Chemotherapy, Adjuvant
10
pegfilgrastim
9
Temozolomide
9
Surgical Procedures, Operative
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Sarcoma
×
tinostamustine
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts